Posters

      Test-Retest Reliability of the Lifestyle Questionnaire: Post-hoc Analysis of a Smoking Cessation Study

      Mainy, N.; Kallischnigg, G.; Zwisele, B.; Ng, W. T.; Langer, P.; Hankins, M.; Haziza, C.; Weitkunat, R.

      Conference date
      Feb 22, 2019
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) 2019
      Link to more information
      Topic
      Summary

      Background: Health-related lifestyle behaviors are linked to many noncommunicable/chronic diseases. The 9-item Lifestyle Questionnaire is based on an adaptation of the Lifestyle Risk Scale and measures seven health-related behaviors: diet, alcohol intake, sleep deficit, physical activity, obesity, smoking, and exposure to secondhand smoke. This study aimed to characterize the test-retest reliability of the Lifestyle Questionnaire.

      Methods: The Lifestyle Questionnaire was administered at screening and baseline visits of a multicenter (42 sites), multiregional (Germany, Japan, Poland, U.K., U.S.) smoking cessation study in healthy smokers willing to quit. Agreement was assessed by Cohen’s weighted kappa coefficient for scale items. Intra-class correlation (ICC) was calculated for the global score. Additional stratification analyses were undertaken by gender, age, income, education, country, body mass index, and days between assessment at Visit 1 and 2.

      Results: 1,184 subjects (50.1% male) were enrolled. The results showed high agreement between screening and baseline visits, especially for the item on smoking behavior.

      Conclusions: The Lifestyle Questionnaire is a reliable measure for clinical and epidemiological studies characterizing potential behavioral confounders. The Lifestyle Questionnaire, together with existing translations in six languages, is distributed on PROQOLID™.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.